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Editor’s key points
† The authors review the
evidence for the
continued use of standard
laboratory tests of
coagulation.
† They conclude that there
is minimal evidence for
the use of standard
laboratory tests in guiding
the management of
perioperative bleeding.
Summary. Standard laboratory coagulation tests (SLTs) such as prothrombin time/
international normalized ratio or partial thromboplastin time are frequently used to assess
coagulopathy and to guide haemostatic interventions. However, this has been challenged
by numerous reports, including the current European guidelines for perioperative bleeding
management, which question the utility and reliability of SLTs in this setting. Furthermore,
the arbitrary definition of coagulopathy (i.e. SLTs are prolonged by more than 1.5-fold) has
been questioned. The present study aims to review the evidence for the usefulness of SLTs
to assess coagulopathy and to guide bleeding management in the perioperative and
massive bleeding setting. Medline was searched for investigations using results of SLTs as a
means to determine coagulopathy or to guide bleeding management, and the outcomes
(i.e. blood loss, transfusion requirements, mortality) were reported. A total of 11 guidelines
for management of massive bleeding or perioperative bleeding and 64 studies investigating
the usefulness of SLTs in this setting were identified and were included for final data
synthesis. Referenced evidence for the usefulness of SLTs was found in only three
prospective trials, investigating a total of 108 patients (whereby microvascular bleeding was
a rare finding). Furthermore, no data from randomized controlled trials support the use of
SLTs. In contrast, numerous investigations have challenged the reliability of SLTs to assess
coagulopathy or guide bleeding management. There is actually no sound evidence from
well-designed studies that confirm the usefulness of SLTs for diagnosis of coagulopathy or
to guide haemostatic therapy.
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Perioperative management of coagulopathic bleeding
requires timely haemostatic intervention using allogeneic blood
products, administration of coagulation factor concentrates,
or both. To guide these interventions, fast laboratory workup
is essential. If it comes to the question which laboratory test
should be performed to assess haemostasis, current guidelines
usually refer to standard plasma coagulation tests (SLTs),
that is, prothrombin time (PT)/international normalized ratio
(INR) and activated partial thromboplastin time,1 – 7 while
viscoelastic tests (i.e. thrombelastography) are less commonly
advocated.7 Although the complete panel of standard co-
agulation testing almost always covers additional measure-
ments of fibrinogen and platelet count, interpretation of SLTs
is most frequently used to assess coagulopathy. Generally
speaking, coagulopathy is presumed when SLTs are prolonged
by more than 1.5-fold, although the evidence to support
this degree of prolongation as diagnostic of coagulopathy is
limited.
However, there are major limitations to these SLTs. These
tests are time-consuming (with turnaround times sometimes
longer than 60 min)8 and, as a consequence, they are often
omitted in situations of severe bleeding, where prompt treat-
ment must be ensured. In addition, if the results of PT/aPTT
are more than 1.5 times prolonged, the treatment options
range from transfusion of fresh-frozen plasma (FFP) to admin-
istration of coagulation factor concentrates such as prothrom-
bin complex concentrates (PCC) or activated recombinant
factor VII. Notably, all these treatment options may be linked
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to serious side-effects, and their administration should be
rigorously justified.
More importantly, we need to question what information
we obtain from a PT or aPTT. In routine clinical practice, PT
and aPTT are commonly used either for bleeding risk assess-
ment before an invasive procedure or, as will be the focus in
this review, for the assessment of the haemostasis profile
with respect to detection of underlying coagulopathy and
guiding subsequent blood component therapy. In fact, PT/
INR and aPTT are plasma-based coagulation tests that were
basically designed to monitor vitamin K antagonists and
heparin, respectively,9 and to assess coagulation factor defi-
ciencies. These latterassays were not intended to monitor peri-
operative coagulation disorders, predict bleeding, or to guide
bleeding therapy in the perioperative setting.10 – 14
This review aims to assess the evidence for using SLTs in the
perioperative setting or massive bleeding management for
diagnosis of coagulopathy and guidance of bleeding therapy,
and also to assess the evidence for using the widely accepted
trigger of ≥1.5-fold prolongation of SLTs.
Methods
Ovid Medline (between 1950and November2013) wassearched
for suitable studies using the following search terms: ‘standard
laboratory tests’ or ‘international normalised ratio’ or ‘in-
ternational normalized ratio’ or INR or prothrombin time or
‘activated partial thromboplastin time’ or aPTT and (guid* or
transfus*). Only English language, non-animal studies were
included. The following terms were excluded from the search:
heparin or warfarin or coumadin or coumarin oracenocoumarol
oranticoagula*. An initial screen was carried out, which involved
reading titles only and rejecting papers based on topic: haemo-
philia/hemophilia, (chronic) liver disease, liver transplantation,
cirrhosis, leukaemia, hepatitis, thalassaemia, lupus, inherited/
congenital, and carcinoma. The second screen involved
reading the abstracts of the papers that made it through the
initial screen. Papers were included if PT, INR, or aPTT were mea-
sured, a threshold for the results of the SLTs was given to deter-
mine coagulopathy or the results were used to guide treatment,
and the outcomes of interest for this review (blood loss, time
to haemostasis, transfusion requirements, mortality) were
reported. This screen removed 278 hits leaving 109 hits to be
included in the final screen, which involved reading the full
papers. Inaddition,Ovid Medlinewas checkedforbleedingman-
agement guidelines from national Societies or Boards. Special
focus was set at the referenced literature that supports the
ongoing recommendations to use SLT and the coupled trigger
levels.
The literature search was conducted by Meridian Health-
Comm Ltd (Plumley, UK) and thereafter independently
screened by two authors (H.S. and T.H.). Disparities in the
literature search were resolved by consensus.
Results
The initial search revealed 1123 records for SLTs and 18 for
bleeding management guidelines. After refining the search
by applying exclusion criteria and further screening by full
paper reading, a total of 64 studies were included for final
data synthesis. The full process of literature search was dis-
played in Figure 1.
The recommended methods of monitoring/diagnosing
coagulopathy in major haemorrhage using laboratory coagu-
lation tests and the recommended bleeding management
within the 11 identified current bleeding management guide-
lines are summarized in Table 1. The referenced literature for
supporting these recommendations is given in Table 2.
The traditional trigger of using a ≥1.5-fold prolongation of
aPTT/PT as a transfusion trigger was identified in six out of
the 11 published guidelines for bleeding management. Screen-
ing of referenced literature within these guidelines revealed
that these triggers were not based on high-quality prospective
data but rather on retrospective data analysis (Table 2). Eight
publications in total were referenced within these guidelines
to justify the traditional SLT trigger. Two of them were review
papers without original data;27 29 one reported recommenda-
tions from a national expert panel,28 two provided data from
retrospective observational data analyses of a trauma registry
and medical charts, respectively,20 22 and finally, three pro-
vided data from prospective observational studies.21 23 31 In
those three prospective studies, data were reported from a
total of 108 patients (72 who underwent major surgery and
36 trauma patients afteradmission to the hospital) were inves-
tigated, but of these, only nine patients experienced diffuse
microvascular bleeding and a prolonged PT/aPTT≥1.8. Analys-
ing data from patients who underwent major surgery revealed
that in one study, only two patients showed PT/aPTT.1.5-fold
prolonged, while no thresholds for PT/aPTT were given in the
second study.
Discussion
Numerous guidelines and publications encourage the use of
SLTs for diagnosis of coagulopathy during perioperative and
massive bleeding and to base transfusion therapy upon pro-
longed thresholds of these SLTs.1 – 6 15 30 33 34 This concept,
however, has been challenged by more recently published
data questioning the usefulness of SLTs and especially the pro-
posed triggers to initiate transfusion therapy in these set-
tings.11 18 24 26 35 – 42 Based on the data of the present review,
there is no high-quality evidence to support that the tradition-
ally applied trigger levels of ≥1.5-fold prolongation of aPTT/PT
or INR are of great help to diagnose whether a patient suffers
from coagulopathic bleeding or if any bleeding therapy
should be initiated. Notably, all referenced evidence within
the guidelines recommending the use of SLTs were eithercross-
referenced between guidelines without providing clear data, or
relate to very sparse, low-quality published literature. The most
frequently referenced evidence of all screened literature is a
prospective study from Ciavarella and colleagues21 who inves-
tigated haemostasis in 36 patients after admittance to the
emergency room in 1986. In that study, diffuse microvascular
bleeding was observed in nine out of 36 patients only, while
four of these nine patients experienced fibrinogen levels
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,0.5 mg dl21, whereby valid interpretation of the results of
SLTs seemed to be impossible. However, the authors concluded
that if fibrinogen levels were adequate, PT or PTT ratios pro-
longation≥1.8 is a reliable predictorof FVor FVIII levels,20%.
In fact, it seems as if the rationale for using PT/INR or aPTT
triggers stem mostly from trauma databases that demon-
strated that prolonged SLTs were frequently correlated with
increased mortality. In a large retrospective analysis of more
than 35 000 trauma patients admitted to the emergency
room, an INR of ≥1.3 was linked to a 6.3-fold increased risk
of in-hospital mortality.20 However, it was not addressed if
those prolonged SLTs were associated with increased bleeding
or transfusion requirements. Using the trigger of 1.5-fold pro-
longation of SLTs, data from a retrospective study in adult
trauma patients (n¼3646)43 and prospective data in paediatric
trauma patients (n¼102)44 demonstrated that prolongations
of SLTs were correlated with higher transfusion requirements
and mortality. Similar observations were made in critically ill
patients, whereby prolonged PT was independently associated
with greater intensive care unit mortality.45 However, the
actual reason for the increase in mortality cannot be answered
by an abnormal baseline test.
SLTs are poor predictors of bleeding and PT/aPTT values
.1.5-fold are not highly correlated to clinically relevant
bleeding.31 46 47 The PT and aPTT evaluate quantities of co-
agulation factors and do not evaluate thrombin potential,
which is arguably a better predictor of bleeding risk. A
single coagulation factor deficiency of ,30% (0.30 IU ml21)
will lead to prolongation of the PT or aPTT, but when multiple
factors are diminished, the PT and aPTT become variably and
less predictably prolonged.21 48 – 50 Massive bleeding can be
characterized as acquired deficiency of more than just one
coagulation factor, and multiple factor deficiency is account-
able for greater prolongation of SLTs than single factor defi-
ciencies.48 51 Another major determinant of measuring SLTs
is fibrinogen level below 80 mg dl21 that may result in pro-
longed SLT results.52 This is of great importance as fibrinogen
deficiency occurs early during treatment of massive blood
loss and thus may have frequent impact on the results of
SLTs.30
There are various other well-known limitations that should
be emphasized for interpretation of SLTs: all these tests are
performed in plasma without platelets or red cells at a standar-
dized temperature, and may not be able to correctly diagnose
complex settings of fibrinogen deficiency, heparin effects, or fi-
brinolysis.53 In addition, using different commercially available
reagents for SLTs, it has been demonstrated that the least sen-
sitive combination of reagents used for PT and aPTT testing
Records indentified through
database searching:
– SLT (n=1123)
– bleeding management guidelines (n=18)
Records excluded
(n=697)
Records excluded
(n=324)
Full text articles
excluded (n=56)
Records after duplicates removed
(n=1141)
Records screened
– SLT (n=429)
– bleeding management guidelines (n=15)
Full text articles assessed
for eligibility
– SLT (n=109)
– bleeding management guidelines (n=11)
Articles included in data synthesis
– SLT (n=53)
– bleeding management guidelines (n=11)
Inclusion/exclusion
criteria applied
Fig 1 Flow diagram of literature search.
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would have suggested coagulopathy in only two out of 16
patients, while the most sensitive set of reagents suggested
therapy in all patients.54
Besides the methodological limitations, the clinically most
important problem is that all SLTs are unacceptably time-
consuming which may frequently result in omission of SLT
measurements or transfusion without laboratory guidance.8 55
This may explain why there is a widespread inappropriate use
of FFP transfusion,56 or the implementation of transfusion
guidelines based on viscoelastic testing (e.g. ROTEMw) have
lowered transfusion requirements.57–59
Although the time to test results could be sped up by the use
of point-of-care devices for measuring PT/INR, there is a high
variability in reported results and thus they may not be useful
for identification or exclusion of patients with coagulopathy
after trauma.8 60
Notably, transfusion of FFP without clear indications is per-
formed frequently in the medical community56 61 and people
Table 1 Recommended laboratory coagulation testing in current guidelines
Guideline (year) Recommended monitoring for coagulopathy Recommended bleeding management
American Society of Anesthesiologists Task Force
on Perioperative Blood Transfusion and Adjuvant
Therapies (2006)1
Platelet count, PT or INR, aPTT. Other tests may
include fibrinogen level, assessment of platelet
function, thromboelastogram, D-dimers, and
thrombin time
Transfusion of FFP for correction of excessive
microvascular bleeding in the presence of:
† PT .1.5 times normal
† INR .2.0
† aPTT .2 times normal
Guidelines Blood transfusion and the
anaesthetist: management of massive
haemorrhage. Association of Anaesthetists of
Great Britain and Ireland (2010)15
Full blood count, PT and aPTT, Clauss fibrinogen.
ROTEMw or TEGw if available. Fibrinogen level is
more sensitive than the PT and aPTT to a
developing dilutional or consumptive
coagulopathy
PT and aPTT . 1.5 times normal is predictive
of microvascular bleeding. Transfusion of FFP
to prevent microvascular bleeding if senior
clinician anticipates a massive haemorrhage
Guidelines on the management of massive blood
loss. British Committee for Standards in
Haematology (2006)6
Full blood count, PT, aPTT, thrombin time,
Fibrinogen (Clauss method)
Administration of FFP to maintain PT and
aPTT,1.5 times control
Guidelines for the use of fresh-frozen plasma,
cryoprecipitate and cryosupernatant. British
Committee for Standards in Haematology, Blood
Transfusion Task Force (2004)5
Traditional clotting tests (PT, aPTT, thrombin
time), platelet count, and near-patient tests
such as the thromboelastogram
Whether and how much FFP should be used
for treating a patient with major blood loss
should be guided by timely tests of
coagulation (including near-patient tests);
however, no clear thresholds given because
of paucity of data
Coagulation management in trauma-related
massive bleeding. Recommendations of the Task
Force for Coagulation of the Austrian Society of
Anesthesiology, Resuscitation and Intensive
Care Medicine (2010)16
Viscoelastic tests recommended (e.g. ROTEMwor
TEGw), and platelet count (function)
Targeted administration of purified
coagulation factors based on ROTEMw or
TEGw; PT (Quick’s value ,30%) may be
alternatively used to guide administration
of PPC/FFP
Scandinavian guidelines—‘The massively
bleeding patient’ (2008)17
Thromboelastogram (TEGw) superior with regard
to identifying and treating clinically relevant
coagulopathies
Targeted administration of FFP/coagulation
factor concentrates based on TEGw
German Medical Association. Cross-sectional
guidelines for therapy with blood components
and plasma derivates (2009)2
PT, aPTT, fibrinogen, platelet count FFP transfusion if PT (Quick’s value) ,50%
or aPTT .45 s in the presence of diffuse
microvascular bleeding
Management of severe perioperative bleeding.
Guidelines from the European Society of
Anaesthesiology (2013)18
Thromboelastometry should be preferably used
to identify coagulopathy and guide treatment
during obstetric bleeding, cardiovascular
surgery, emergency radiological/surgical
interventions, orthopaedic surgery and
neurosurgery, visceral and transplant surgery,
and paediatric surgery. Platelet count (and
function). PT/INR/aPTT prolongation can be
misleading in patients with chronic liver disease
Recommendation to substitute fibrinogen if
plasma concentration is ,1.5–2.0 g litre21 or
functional fibrinogen deficit in ROTEM/TEG.
Prolonged INR/PTalone is not an indication for
PCC. In VKA-treated patients, INR .1.5 with
life-threatening bleeding should trigger
administration of PCC and Vit K. Otherwise,
coagulation therapy should be based on
ROTEM/TEG
Recommendations for the transfusion
management of patients in the intraoperative
period. Italian Society of Transfusion Medicine
and Immunohaematology (2011)4
Monitoring of platelet count, PT, aPTT, fibrinogen,
antithrombin, D-dimer
FFP should be transfused for correction
of microvascular bleeding if PT or aPTT,
expressed as a ratio is .1.5
Management of bleeding and coagulopathy
following major trauma: an updated European
Guideline (2013)7
Measurement of PT, aPTT, fibrinogen and
platelets. Viscoelastic measurements should be
also performed
No trigger levels for PT/aPTT/INR given
Australian Patient Blood Management
Guidelines: Module 1 (2011)19
Platelet count, PT/INR, aPTT, fibrinogen Values indicative of critical physiological
derangement include: PT/aPTT . 1.5 normal,
INR .1.5
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Table 2 Evidence from references within current guidelines (Table 1)
Guideline (year) References within guideline
American Society of Anesthesiologists Task Force on Perioperative Blood
Transfusion and Adjuvant Therapies (2006)1
Recommendations based on a consultant survey response and ASA
membership survey response
No referenced evidence for usefulness of standard laboratory coagulation tests
Blood transfusion and the anaesthetist: management of massive
haemorrhage. Association of Anaesthetists of Great Britain and Ireland
(2010)15
Hess, Transfusion 200920
INR or activated PTTratio (aPTTr) increased with increasing injury severity score
of 35 322 trauma patients after admission to trauma centre (retrospective
analysis). An increase in INR or aPTTr demonstrated stepwise relationship with
in-hospital mortality. No clear threshold given
Guidelines on the management of massive blood loss. British Committee for
Standards in Haematology (2006)6
Ciavarella, Br J Haematol 198721
Microvascular bleeding was associated with severe abnormalities of
coagulation factor levels , 20% (PT and aPTT values .1.8 times control).
Prospective study in 36 patients admitted to emergency room, which were
likely to be massively transfused
Guidelines for the use of fresh-frozen plasma, cryoprecipitate and
cryosupernatant. British Committee for Standards in Haematology, Blood
Transfusion Task Force (2004)5
Ciavarella, Br J Haematol 198721
(See above)
Mannucci, Vox Sang 198222
PT .1.2 times normal or aPTT .1.25 times normal were found in 93% of
patients who underwent major surgery (including cardiopulmonary bypass
procedures) and received massive transfusion. Retrospective data analysis of
172 patients
Coagulation management in trauma-related massive bleeding.
Recommendations of the Task Force for Coagulation of the Austrian Society of
Anesthesiology, Resuscitation and Intensive Care Medicine (2010)16
No evidence for usefulness of standard laboratory coagulation tests
Scandinavian guidelines—‘The massively bleeding patient’ (2008)17 No evidence for usefulness of standard laboratory coagulation tests
German Medical Association. Cross-sectional guidelines for therapy with blood
components and plasma derivates (2009)2
Hiippala, Anesth Analg 199523
Fibrinogen deficiency develops earlier than any other haemostatic
abnormality. No trigger levels for PT/aPTT given. Prospective data from 60
patients undergoing major urologic or abdominal surgery
Management of severe perioperative bleeding. Guidelines from the European
Society of Anaesthesiology (2013)18
Abdel-Wahab, Transfusion 200624
No correlation with mild abnormalities of PT, aPTT, and risk of bleeding.
Correction of mildly prolonged PT/INR by transfusion of FFP fails in 99%. Data
from prospective audit from Massachusetts General Hospital after transfusion
of 1091 units of FFP, 2004–5
Matevosyan, J Neurosurg 201125
Prolongation of INR up to 1.7 has haemostatically normal levels of coagulation
factors. Prospective study in 31 neurosurgical patients
de Loyd, Int J Obstet Anesth 201126
Fibrinogen level is most sensitive laboratory parameter for detecting
coagulopathy during obstetric bleeding, and PT is an unhelpful test.
Retrospective analysis of 18 501 deliveries over 3 yr in a large UK city-based
maternity unit
Recommendations for the transfusion management of patients in the
intra-operative period. Italian Society of Transfusion Medicine and
Immunohaematology (2011)4
American Society of Anesthesiologists Task Force on Perioperative Blood
Transfusion and Adjuvant Therapies (2006)1
(See above)
Calder, Can Med Assoc J 199727
Recommendation of an expert panel. No transfusion triggers were given
De Backer, Acta Clin Belg 200828
PT and aPTT are not useful for guidance of FFP transfusion in severe bleeding.
Recommendations from a national guideline based on expert opinion
Hellstern, Thromb Res 200229
FFP transfusion if PT or aPTT is .1.5 times prolonged during acute blood loss
and massive transfusion. Review article. References to Hiippala30 and Murray.31
Hiippala, Vox Sanguinis 199830
Probabilityof coagulopathy increaseswhen aPTTand PTare.1.5 times normal.
Hypofibrinogenaemia develops first during massive blood loss. Review Paper.
References to Murray31 and Ciavarella21
Murray, Anesthesiology 198831
Massive transfusion was necessary in seven out of 12 patients during major
surgery; while only two patients showed PT/aPTT .1.5. Prospective
observational study in 12 patients
Management of bleeding and coagulopathy following major trauma: an
updated European Guideline (2013)7
No evidence for usefulness of standard laboratory coagulation tests
Only data showing the beneficial use of ROTEM/TEG were referenced
Continued
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seem to trust traditional SLT, but retrospective data analyses
have demonstrated that SLT will be normalized in only 34.5%
of cases after FFP transfusion.62
It should be noted that due to changes of modern bleeding
management seen particularly in Europe, for example, PCC
may be used increasingly instead of FFP to treat prolonged
SLT results, which could lead to serious side-effects and high
costs if the use was not justified.
It should be clearly stated that SLTare not per se inappropri-
ate, but have been frequently used to try to answer a question
that they were never designed to be able to answer. It seems as
if the medical community continues to believe in the useful-
ness of SLTs to diagnose coagulopathy, as they do for the (not
existing) predictive value of SLTs to predict risk of bleeding
before invasive procedures.63 However, if no other laboratory
test is available, SLTs may be preferable above no testing. Cer-
tainly, SLTs have considerable utility in managing ongoing
bleeding, when several SLT tests have been taken and a trend
in the change of blood tests can guide further therapy. This is
in fact hard to answer and will be eventually based on local
standards of treatment.
Neither PT/INR noraPTTwere designed to accurately portray
the complex interaction of coagulation factors and inhibitors.
SLTs may often incorrectly be thought to provide information
about overall thrombin generation (TG). A common assump-
tion is that as procoagulant factors decline, TG declinestoo. Im-
portant inhibitors such as antithrombin or protein C, which are
involved in overall TG, are not adequately represented in SLTs.64
But, PT and aPTT measurements terminate when only 5% of
thrombin is generated.65 Therefore, SLTs provide information
only about the very initial process of TG. Studies have revealed
that haemodilution results in a lesser degree of TG than was
expected by the decline of procoagulant factors.66 Dunbar
and Chandler67 observed that dilution of all plasma proteins
to 40% of normal resulted in an increase in tissue factor-
stimulated TG. This finding is related to a simultaneous dilution
of both procoagulant and anticoagulant proteins. Shaz and
colleagues68 investigated 371 trauma patients on ER admis-
sion. Patients were grouped in those with prolonged PT sug-
gestive of trauma-induced coagulopathy (TIC) and those with
normal PT. Despite the fact that FV, FVII, and FXIII were
lower in the TIC group, no difference in markers of TG (pro-
thrombin fragment 1–2 and thrombin–antithrombin com-
plexes) could be observed. Again this observation might be
explained by a simultaneous decrease in both procoagulants
and inhibitors, which is not adequately reflected by SLTs.
However, the question about whether prolonged SLTs are indi-
cative of the requirement for specific haemostatic therapy
needs to be addressed with adequately powered studies.
Analogous findings have been reported from patients with
liver failure. These patients are able to maintain normal TG as
a result of a simultaneous decrease in both pro- and anticoagu-
lant factors.69 In another study on patients with liver cirrhosis
and prolonged PT/INR, Gatt and colleagues70 investigated TG
parameters in cirrhotic patients. Despite a prolonged PT/INR,
TG parameters were consistent with a hypercoagulable
profile. The authors stated that the PT/INR test should not be
used to assess bleeding risk and as a guidance for prophylactic
transfusion of clotting factors.
In conclusion, there are significantshortcomings of SLTs in the
perioperative and major bleeding management setting. First,
these tests were neither designed to accurately reflect compro-
mised TG nor to guide coagulation therapy. In addition, the
applied trigger levels of ≥1.5-fold prolongation of aPTT/PT or
INR .1.5 to initiate bleeding therapy were not supported by
evidence-based data but rather on historically established
habits. In general, SLTs are widely available and frequently
used, but there is no sound evidence from well-designed
studiesthat confirm that SLTs are useful for diagnosis of coagulo-
pathyor to guide haemostatic therapy. Secondly, the turnaround
times of SLTs are too protracted for emergency scenarios, where
quick decision-making is mandatory. Alternatives, such as visco-
elastic analysers, provide data much more quickly and provide a
more comprehensive overview of thewhole coagulationprocess.
However, morewell-designed studies indifferent clinicalsettings
are needed to confirm that these tests are preferable over stand-
ard tests. Thus, it seems questionable how long physicians are
willing to continue using (late) results of SLTs as markerof coagu-
lopathy or guidance for bleeding management. But as always,
old and even bad habits die hard.
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